Brink Therapeutics

High-Level Overview

Brink Therapeutics is a Paris-based biotech startup founded in 2024 that develops next-generation gene editing enzymes called recombinases to enable advanced cell and gene therapies, particularly for CAR-T treatments targeting hematological cancers, solid tumors, and rare genetic diseases.[1][2] The company addresses limitations of traditional gene-editing tools like programmable nucleases by using recombinases—precise enzymes that modify DNA without double-strand breaks—enhanced through directed evolution, metagenomic discovery, and AI-driven design for programmable, scalable genetic modifications.[1][2] Initially focusing on CAR-T cell therapies, Brink serves patients with hard-to-treat cancers and genetic disorders by enabling safer in vivo genome editing, with early momentum from a €3.5 million seed round in 2025 led by Kurma Partners to expand its team to 15 specialists and validate five novel recombinases by end-2026.[1][2]

Origin Story

Brink Therapeutics was founded in September 2024 by Dr. Jonathan Naccache (ESPCI) and Dr. Harry Kemble (INSERM/ESPCI), two accomplished scientists whose prior work contributed to the success of the diagnostic startup Detect.[1] The idea emerged from their expertise in molecular and cellular biology, aiming to pioneer recombinase-based gene editing as a safer alternative to existing "genetic scissors" that risk off-target effects and genomic instability.[1][2] Early traction came swiftly with the €3.5 million seed funding in 2025, backed by Kurma Partners, Kima Ventures, BREEGA, Plug and Play Tech Center, and business angels, providing capital to build a data library for AI-driven enzyme design and kickstart R&D.[2]

Core Differentiators

• Recombinase Platform: Harnesses naturally precise enzymes for DNA sequence-specific modifications without double-strand breaks, outperforming nucleases in safety and accuracy for therapeutic applications.[1][2]
• AI-Accelerated Development: Combines in vitro directed evolution, metagenomic discovery, and generative AI to screen billions of recombinase sequences rapidly, generating proprietary data to refine programmable enzymes.[1][2]
• Versatile Applications: Starts with advanced CAR-T for hematological cancers but scales to in vivo editing for solid tumors and rare diseases, unlocking broader cell therapy potential.[1][3]
• Team and Milestone Focus: Plans to recruit 15 experts in molecular biology, cellular biology, bioinformatics, and AI, targeting validation of five high-efficacy recombinases in human cells by 2026.[1][2]

Role in the Broader Tech Landscape

Brink Therapeutics rides the wave of next-generation gene editing, where recombinases address CRISPR's limitations like off-target cuts and delivery challenges, aligning with the booming CAR-T market projected to expand amid demands for in vivo therapies that treat patients without ex vivo cell extraction.[1][2][3] Timing is ideal post-2024 funding surge in European biotech, fueled by AI integration in drug discovery and investor focus on precision medicine from firms like Kurma Partners, which targets innovative therapeutics.[2] Market forces favoring Brink include rising solid tumor therapy needs and rare disease investments, positioning the company to influence the ecosystem by open-sourcing data insights or partnering for scalable production, much like prior gene-editing pioneers.[1][2]

Quick Take & Future Outlook

Brink's near-term path centers on hitting 2026 recombinase milestones, team scaling, and AI data library expansion to prototype CAR-T candidates, potentially attracting Series A funding amid Europe's biotech momentum.[1][2] Trends like AI-optimized enzymes and in vivo cell therapies will propel growth, evolving Brink from a seed-stage innovator to a platform leader partnering with big pharma for global trials. As a fresh entrant solving gene editing's precision bottleneck, Brink exemplifies how founder-driven science can redefine accessible therapies, echoing its Detect roots in transformative biotech.